GlassScriptPhysician profile
Umesh A Badami
NPI 1477549087
$8,931.29
in general payments reported to CMS, 2019-2025
36 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,213 · 2020: $2,657 · 2021: $1,262 · 2022: $1,917 · 2023: $140 · 2024: $293 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787 · Grant: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.03 |
| Grant | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,296.95 | 2019-2020 | |
| Abiomed | $1,808.32 | 2021-2025 | Impella |
| Medtronic, INC. | $1,293.78 | 2021-2024 | Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $319.04 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $256.23 | 2019-2025 | |
| Boston Scientific Corporation | $237.52 | 2019-2025 | General - Structural Heart, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $219.40 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $170.08 | 2019-2025 | Lifevest |
| Abbott Laboratories | $156.63 | 2019-2024 | Cardiomems |
| Sanofi-Aventis U.S. LLC | $143.73 | 2019 | |
| Amgen INC. | $132.82 | 2019-2020 | |
| Recor Medical INC | $114.57 | 2025 | Paradise Ultrasound Renal Denervation System |
| Pfizer INC. | $98.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $78.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.69 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $61.07 | 2019-2020 | |
| Lundbeck LLC | $58.56 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $55.72 | 2024-2025 | Assure Wcd |
| Ge Healthcare | $45.88 | 2020 | |
| Biotronik INC. | $32.18 | 2020 | |
| Cook Medical LLC | $29.64 | 2021-2025 | Cook Celect |
| Actelion Pharmaceuticals US, INC. | $26.58 | 2023 | Opsumit, Uptravi |
| Atricure, INC. | $25.38 | 2022 | |
| Terumo Medical Corporation | $22.97 | 2023 | Tr Band |
| Arbor Pharmaceuticals, INC. | $22.38 | 2019 | |
| Lantheus Medical Imaging, INC. | $19.97 | 2022 | |
| Cordis US Corp. | $18.04 | 2024 | Mynx Venous Vcd |
| Biosense Webster, INC. | $17.53 | 2020 | |
| Scpharmaceuticals INC. | $16.61 | 2025 | |
| Teleflex LLC | $15.31 | 2020 | |
| Siemens Medical Solutions USA, INC. | $15.21 | 2019 | |
| Philips North America LLC | $15.01 | 2025 | Azurion 7 M20 |
| Irhythm Technologies, INC. | $13.92 | 2019 | |
| Cardinal Health 200 LLC | $13.54 | 2019 | |
| Cardiovascular Systems INC. | $10.85 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umesh Badami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.